PapersFlow Research Brief
Pulmonary Hypertension Research and Treatments
Research Guide
What is Pulmonary Hypertension Research and Treatments?
Pulmonary Hypertension Research and Treatments encompasses studies on the diagnosis, assessment, and management of pulmonary hypertension, with a focus on right heart evaluation via echocardiography, survival prediction, vascular remodeling, endothelial dysfunction, BMPR2 mutations, and hemodynamic classification.
The field includes 93,426 published works on pulmonary hypertension diagnosis, treatment guidelines, and right heart assessment using echocardiography. Key contributions cover hemodynamic definitions, clinical classification updates, and survival predictors based on right ventricular function. Research also addresses endothelial nitric oxide synthesis and vascular changes in pulmonary hypertension.
Topic Hierarchy
Research Sub-Topics
Right Heart Assessment by Echocardiography
Echocardiographic assessment of the right ventricle and pulmonary pressures uses strain imaging, TAPSE, and tricuspid regurgitation velocity. Guidelines standardize protocols for PH screening and monitoring disease progression.
Pulmonary Hypertension Treatment Guidelines
ESC/ERS guidelines update risk assessment, pharmacotherapy like PDE5 inhibitors, and combination regimens based on hemodynamic response. Research validates algorithms for WHO group classifications and transplant timing.
BMPR2 Mutations in Pulmonary Arterial Hypertension
BMPR2 mutations underlie familial and idiopathic PAH, disrupting TGF-beta signaling and vascular proliferation. Genetic studies identify penetrance, modifiers, and therapeutic targets like BMP agonists.
Pulmonary Vascular Remodeling in Hypertension
Vascular remodeling in PH involves smooth muscle hypertrophy, intimal fibrosis, and plexiform lesions driven by hypoxia and inflammation. Pathological and animal model studies test anti-remodeling agents.
Survival Prediction in Pulmonary Hypertension
Survival prediction uses multiparametric risk scores incorporating 6MWD, NT-proBNP, hemodynamics, and echo indices. Registry analyses refine tools like REVEAL 2.0 for treatment decisions.
Why It Matters
Pulmonary hypertension guidelines from Galiè et al. (2015) in the "2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension" provide evidence-based strategies for diagnosis and therapy, assisting clinicians in managing patients with conditions like mean pulmonary arterial pressure ≥25 mmHg. Rudski et al. (2010) in "Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography" standardize right heart imaging, enabling non-invasive survival prediction linked to right ventricular hemodynamics as shown by D’Alonzo et al. (1991) in "Survival in Patients with Primary Pulmonary Hypertension," where mortality correlates with mean pulmonary artery pressure, right atrial pressure, and cardiac index. Simonneau et al. (2018) in "Haemodynamic definitions and updated clinical classification of pulmonary hypertension" updated the pressure threshold to 20 mmHg based on normal subject data (mean 14.0±3.3 mmHg), improving classification across five groups and guiding targeted treatments.
Reading Guide
Where to Start
"2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension" by Galiè et al. (2015), as it offers a complete diagnostic and treatment framework with algorithms suitable for initial orientation.
Key Papers Explained
Galiè et al. (2015) in "2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension" builds on Galiè et al. (2009) in "Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension..." by updating evidence and risk tools. Rudski et al. (2010) in "Guidelines for the Echocardiographic Assessment of the Right Heart in Adults..." provides diagnostic methods referenced in both guidelines. Simonneau et al. (2018) in "Haemodynamic definitions and updated clinical classification of pulmonary hypertension" refines definitions from Simonneau et al. (2013) in "Updated Clinical Classification of Pulmonary Hypertension," influencing Humbert et al. (2022) in "2022 ESC/ERS Guidelines...".
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Humbert et al. (2022) in "2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension" represents the latest consensus on diagnostics and therapies. No recent preprints or news in the last 12 months indicate steady guideline evolution without major disruptions.
Papers at a Glance
Frequently Asked Questions
What are the current guidelines for diagnosing pulmonary hypertension?
The "2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension" by Galiè et al. (2015) outline diagnostic algorithms using echocardiography and right heart catheterization. Confirmation requires mean pulmonary arterial pressure ≥25 mmHg at rest. These guidelines, endorsed by multiple societies, integrate risk assessment for treatment decisions.
How is the right heart assessed in pulmonary hypertension?
"Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography" by Rudski et al. (2010) provides standardized measurements for right ventricular size, function, and pressures. Echocardiography evaluates tricuspid regurgitation velocity and right atrial area for non-invasive diagnosis. These metrics predict survival when combined with hemodynamics.
What is the hemodynamic definition of pulmonary hypertension?
"Haemodynamic definitions and updated clinical classification of pulmonary hypertension" by Simonneau et al. (2018) defines it as mean pulmonary arterial pressure >20 mmHg, revising the prior 25 mmHg threshold based on normal values of 14.0±3.3 mmHg. This update refines precapillary and postcapillary distinctions. It supports five clinical groups for targeted therapy.
What predicts survival in primary pulmonary hypertension?
"Survival in Patients with Primary Pulmonary Hypertension" by D’Alonzo et al. (1991) links mortality to right ventricular hemodynamic function via mean pulmonary artery pressure, mean right atrial pressure, and cardiac index. An equation using these variables characterizes prognosis. Prospective validation enables risk stratification.
How has the clinical classification of pulmonary hypertension evolved?
"Updated Clinical Classification of Pulmonary Hypertension" by Simonneau et al. (2013) maintains five groups including pulmonary arterial hypertension and chronic thromboembolic disease. The 2022 update in "2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension" by Humbert et al. (2022) refines diagnostics and therapies. Classifications guide etiology-specific management.
What role does endothelial dysfunction play in pulmonary hypertension?
"Vascular endothelial cells synthesize nitric oxide from L-arginine" by Palmer et al. (1988) demonstrates nitric oxide production, relevant to endothelial dysfunction in pulmonary hypertension. Impaired synthesis contributes to vascular remodeling. This informs therapies targeting vasodilation.
Open Research Questions
- ? How can BMPR2 mutations be targeted for heritable pulmonary arterial hypertension therapy?
- ? What are precise noninvasive predictors of survival beyond echocardiographic right heart metrics?
- ? How does vascular remodeling differ across the five clinical groups of pulmonary hypertension?
- ? Can updated hemodynamic thresholds improve early detection in at-risk populations?
- ? What interventions best address right heart failure in advanced pulmonary hypertension?
Recent Trends
The field has 93,426 works with growth data unavailable over five years.
Humbert et al. in "2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension" (3197 citations) updates prior ESC/ERS guidelines, lowering the hemodynamic threshold per Simonneau et al. (2018) findings of normal mPAP at 14.0±3.3 mmHg.
2022Research Pulmonary Hypertension Research and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pulmonary Hypertension Research and Treatments with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers